• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Athira Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    4/16/25 4:05:09 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    8-K
    false000162046300016204632025-04-152025-04-15

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 15, 2025

     

    Athira Pharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-39503

    45-3368487

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

     

    18706 North Creek Parkway, Suite 104
    Bothell, WA 98011

    (Address of principal executive offices, including zip code)

     

    (425) 620-8501

    (Registrant’s telephone number, including area code)

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

    ATHA

    The Nasdaq Stock Market LLC 
    (The Nasdaq Global Select Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act). ☐

     

     

     

     


     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On April 15, 2025, Athira Pharma, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”).

    As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 18, 2024, the Company received a notification letter (the “Bid Price Notice”) from Nasdaq on October 16, 2024 notifying the Company that, based on the closing bid price of the Company’s Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company had an initial compliance period of 180 calendar days, or until April 14, 2025, to regain compliance with the Minimum Bid Price Requirement. In response, on April 4, 2025, the Company filed an application to transfer the listing of its Common Stock from The Nasdaq Global Select Market to The Nasdaq Capital Market (the “Transfer Application”) and request the additional 180-day compliance period offered on that market.

    As a result of the Approval, the Company has been granted an additional 180-day grace period, or until October 13, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company’s common stock will be transferred to the Nasdaq Capital Market effective as of the opening of business on April 17, 2025, and will continue to trade under the symbol “ATHA.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must comply with Nasdaq’s continued listing requirements and standards.

    To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. The Company is seeking stockholder approval to effect a reverse stock split at its 2025 annual meeting of stockholders.

     

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Company’s expectations, strategy, plans or intentions. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, the Company’s intent and ability to regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on The Nasdaq Capital Market, and the potential implementation of a reverse stock split.

     

     


     

    All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company, deal with future events, and are subject to various risks and uncertainties, including the risks that the Company may not meet the Minimum Bid Price Requirement by the required compliance date or in the future, that the Company may not otherwise meet the requirements for continued listing under the Nasdaq listing rules, that Nasdaq may not grant the Company relief from delisting if necessary, that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, and that any potential reverse stock split attempted may not occur, among other risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from the Company’s current expectations are more fully described in the Company’s Annual Report on Form 10-K filed with the SEC on February 27, 2025, any subsequently filed Quarterly Reports on Form 10-Q, and its other reports, each as filed with the SEC. Except as required by law, the Company assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    Athira Pharma, Inc.

     

     

     

     

    Date:

    April 16, 2025

    By:

    /s/ Mark Litton

     

     

     

    Mark Litton

     

     

     

    President and Chief Executive Officer

     

     

     

     


    Get the next $ATHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates. "We look forward to the opportunity to continue to advance ATH-1105 as a potential therapy for ALS, which in various preclinical models has demonstrated a consistent ability to

      2/27/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

      BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada. "The preclinical data presented demonstrate for the first time the neuroprotective effects of ATH-1105 in human models of ALS, including human iPSC-derived motor neurons expressing the SOD1-A4V mutation," said Kevin

      12/6/24 5:30:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

      BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. "We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating drug candidate has improved blood-brain-barrier penetration and pharmacokinetic properties. Specifically, preclinically ATH-1105 has shown a consistent ability in various ALS models to reduce plasma neurofi

      11/7/24 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Financials

    Live finance-specific insights

    See more
    • Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

      On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across

      3/24/22 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

      BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa

      3/17/22 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

      Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors. Dr. Litton will also

      10/21/21 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert

      4/A - Athira Pharma, Inc. (0001620463) (Issuer)

      3/12/25 5:20:38 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      3/4/25 4:31:26 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      3/4/25 4:30:43 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Athira Pharma Inc.

      SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)

      11/14/24 4:17:23 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Athira Pharma Inc.

      SC 13G - Athira Pharma, Inc. (0001620463) (Subject)

      11/7/24 1:15:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Athira Pharma Inc.

      SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

      10/31/24 4:16:28 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

      Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

      6/26/24 3:07:15 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athira Pharma downgraded by Mizuho with a new price target

      Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously

      9/19/24 7:34:53 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral

      9/4/24 8:27:09 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by BTIG Research

      BTIG Research downgraded Athira Pharma from Buy to Neutral

      9/4/24 7:28:38 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Athira Pharma Inc.

      SCHEDULE 13G - Athira Pharma, Inc. (0001620463) (Subject)

      4/16/25 4:22:18 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Athira Pharma, Inc. (0001620463) (Filer)

      4/16/25 4:05:09 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Athira Pharma Inc.

      DEFA14A - Athira Pharma, Inc. (0001620463) (Filer)

      4/14/25 4:31:20 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/25/24 7:21:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Perceptive Advisors Llc bought $1,462,895 worth of shares (605,686 units at $2.42) (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      12/29/23 5:24:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Leadership Updates

    Live Leadership Updates

    See more
    • Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

      BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i

      4/15/24 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

      BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D

      5/22/23 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

      New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"

      4/25/22 8:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care